Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up

por Rolla, Simona, De Mercanti, Stefania Federica, Bardina, Valentina, Maglione, Alessandro, Taverna, Daniela, Novelli, Francesco, Cocco, Eleonora, Vladic, Anton, Habek, Mario, Adamec, Ivan, Annovazzi, Pietro Osvaldo Luigi, Horakova, Dana, Clerico, Marinella
Publicado 2022